A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer

Published:2018-01 Issue:1 Volume:30 Page:30-38
ISSN:0936-6555
Container-title:Clinical Oncology
language:en
Short-container-title:Clinical Oncology

Author:

Cagney D.N.,Thirion P.G.,Dunne M.T.,Fleming C.,Fitzpatrick D.,O'Shea C.M.,Finn M.A.,O'Sullivan S.,Booth C.,Collins C.D.,Buckney S.J.,Shannon A.,Armstrong J.G.

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology

Reference38 articles.

1. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur J Cancer,2013

2. European cancer mortality predictions for the year 2012;Malvezzi;Ann Oncol,2012

3. Cancer statistics;Jemal;CA Cancer J Clin,2009

4. Sequential vs concurrent chemoradiation for stage III non–small cell lung cancer: randomized Phase III trial RTOG 9410;Curran;J Natl Cancer Inst,2011

5. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small-cell lung cancer;Aupérin;J Clin Oncol,2010

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non–Small Cell Lung Cancer;JAMA Oncology;2024-03-01

2. Accelerated Hypofractionated Radiotherapy for Centrally Located Lung Tumours Not Suitable for Stereotactic Body Radiotherapy or Chemoradiotherapy;Clinical Oncology;2023-02

3. Short term clinical outcomes of accelerated hypofractionated radiotherapy in inoperable non-small cell lung cancer patients;Reports of Practical Oncology and Radiotherapy;2021-09-30

4. Hypofractionation in Early Stage Non-Small Cell Lung Cancer;Seminars in Radiation Oncology;2021-04

5. Dose and fractionation schedules in radiotherapy for non-small cell lung cancer;Translational Lung Cancer Research;2021-04